<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To study the anticancer effects of <z:chebi fb="0" ids="2981">Baicalin</z:chebi> on an orthotopic transplantation mouse model of mismatch repair gene deficient <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Sixty orthotopic transplantation mice model of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line HCT-116 expressing eGFP were established, which were divided randomly into negative controlled group (5% <z:chebi fb="0" ids="32139">NaHCO3</z:chebi>) and 50, 100, 200 mg/kg <z:chebi fb="0" ids="2981">Baicalin</z:chebi> groups </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:mp ids='MP_0003815'>nude</z:mp> mice were treated with intragastric infusion twice a day </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0003815'>Nude</z:mp> mice growth state, average weigh, inhibition rate of transplanted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> and survival state were observed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At 14, 21 and 28 days after treatment with different dose of <z:chebi fb="0" ids="2981">Baicalin</z:chebi>, <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> velocity was significantly slower in the treatment groups, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume was significantly smaller than the controlled group (there were (832 ± 637), (2012 ± 1566) and (2494 ± 1557) mm(3) respectively in 14, 21 and 28 days) (F = 4.433, P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>At the end point of study, survival state of 100 mg/kg group (13/15) was superior to controlled group (8/15) and 200 mg/kg group (8/15) (χ(2) = 4.665 and 3.980, P &lt; 0.05).However, there were no significant differences in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> surface vessel density </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="2981">Baicalin</z:chebi> has statistically significant effects in inhibiting <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in an orthotopic transplantation mouse model of mismatch repair gene deficient <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and 100 mg/kg may be an ideal treatment dose </plain></SENT>
</text></document>